Correct Answer: D. Vincristine, carboplatin and etoposide
The standard chemotherapy regimen for retinoblastoma in India and globally is vincristine, carboplatin, and etoposide (VCE). This combination is the backbone of intra-arterial chemotherapy (IAC) and systemic chemotherapy protocols for retinoblastoma, particularly in eyes amenable to globe-salvaging therapy. Vincristine is a vinca alkaloid that disrupts microtubule formation; carboplatin is a platinum-based agent providing DNA cross-linking; and etoposide is a topoisomerase II inhibitor. Together, they achieve synergistic cytotoxicity against retinoblastoma cells while maintaining acceptable tolerability. This regimen is recommended by the Indian Society of Pediatric Oncology (ISPO) and aligns with international protocols (COG, SIOP). The use of carboplatin over cisplatin in this combination reduces nephrotoxicity and ototoxicity, making it safer for pediatric patients in the Indian setting where follow-up care may be limited. Etoposide penetrates the blood–retinal barrier better than bleomycin, making it more effective for intraocular disease. This is the DOC for globe-salvaging chemotherapy in retinoblastoma.
Why the other options are wrong
A. Vinblastine, etoposide and bleomycin — This is wrong because bleomycin is not part of the standard retinoblastoma regimen. Bleomycin causes pulmonary fibrosis and is not effective for intraocular disease due to poor blood–retinal barrier penetration. The combination lacks carboplatin, which is essential for platinum-based synergy in retinoblastoma chemotherapy. NBE may include this to test knowledge of which agents are actually used versus those used in other pediatric malignancies (e.g., Hodgkin lymphoma). B. Vinblastine, vincristine and cisplatin — This is wrong because it uses both vinblastine and vincristine together, which is redundant (both are vinca alkaloids with overlapping toxicity profiles). Cisplatin is less preferred than carboplatin in pediatric retinoblastoma due to higher nephrotoxicity and ototoxicity—critical concerns in Indian pediatric populations with limited access to dialysis and hearing rehabilitation. The standard regimen replaces vinblastine with carboplatin, not cisplatin. C. Vinblastine, vincristine and etoposide — This is wrong because it includes both vinblastine and vincristine (redundant vinca alkaloids) and lacks carboplatin, the platinum agent essential for synergistic DNA damage in retinoblastoma. While etoposide is correct, the absence of a platinum agent significantly reduces efficacy. This combination may confuse students who remember 'vincristine + etoposide' but forget that carboplatin (not vinblastine) is the third agent in the standard VCE regimen.
High-Yield Facts
- VCE regimen (vincristine, carboplatin, etoposide) is the standard chemotherapy for retinoblastoma globe-salvaging therapy in India and internationally.
- Carboplatin is preferred over cisplatin in pediatric retinoblastoma because it has lower nephrotoxicity and ototoxicity.
- Etoposide penetrates the blood–retinal barrier better than bleomycin, making it effective for intraocular disease.
- Intra-arterial chemotherapy (IAC) using VCE is increasingly used in India for unilateral retinoblastoma to preserve vision and avoid external beam radiation.
- Vincristine is a vinca alkaloid that disrupts microtubule formation; it is the backbone of most pediatric cancer regimens including retinoblastoma.
- Enucleation remains the DOC for advanced bilateral disease or when globe salvage fails; chemotherapy is adjuvant in such cases.
Mnemonics
VCE for Retinoblastoma Vincristine + Carboplatin + Etoposide = standard retinoblastoma chemotherapy. Remember: Carboplatin (not cisplatin) for safety in children; Etoposide (not bleomycin) for blood–retinal barrier penetration. Why NOT cisplatin in kids? Cisplatin = Crash kidneys + Crash ears (nephrotoxicity + ototoxicity). Use Carboplatin instead in pediatric retinoblastoma for safer toxicity profile.
NBE Trap
NBE pairs "vincristine + etoposide" (which are correct) with either vinblastine (redundant vinca) or cisplatin (wrong platinum agent) to trap students who partially recall the regimen but confuse the third agent. The key discriminator is recognizing that carboplatin—not cisplatin, not bleomycin, not vinblastine—completes the standard VCE triplet.
Clinical Pearl
In Indian tertiary centers, intra-arterial chemotherapy (IAC) with VCE via ophthalmic artery catheterization is increasingly preferred over enucleation for unilateral retinoblastoma, as it preserves vision and avoids the psychological trauma of eye loss in children. However, systemic VCE remains the backbone for bilateral disease and metastatic retinoblastoma.
_Reference: OP Ghai Pediatric Nursing Ch. 18 (Malignancies); Bailey & Love Ch. 52 (Pediatric Surgery); Harrison Ch. 81 (Oncology in Children)_